ArticleCellular oncology (Dordrecht, Netherlands)2022
Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
Article in Cellular oncology (Dordrecht, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- The impact of gut microbiota on leukemia and prospects for novel therapies.Infectious medicine · 2026Review
- Bitter gourd bioactive peptide alleviates neuronal ferroptosis after spinal cord ischemia-reperfusion injury, combined with emerging cell and animal models.Frontiers in nutrition · 2026Article
- Bitter gourd peptides (BG) alleviate lupus progression in mice through regulation of miR-146a/BRD4 axis in macrophages.Frontiers in immunology · 2026Article
- Anti-Cancer Bioactive Peptide Induces Apoptosis in Gastric Cancer Cells through TP53 Signaling Cascade.Protein and peptide letters · 2025Article
- N6-methyladenosine RNA modifications: a potential therapeutic target for AML.Annals of hematology · 2024Review
- Small molecule inhibitors targeting mJournal of hematology & oncology · 2024Review
- Targeting BMAL1 reverses drug resistance of acute myeloid leukemia cells and promotes ferroptosis through HMGB1-GPX4 signaling pathway.Journal of cancer research and clinical oncology · 2024Article
- Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects.Frontiers in oncology · 2024Review
- Design of ion channel blocking, toxin-like Kunitz inhibitor peptides from the tapeworm, Echinococcus granulosus, with potential anti-cancer activity.Scientific reports · 2023Article
- RNA modifications in hematological malignancies.International journal of hematology · 2023Review
- Aberrant RNA mCell death & disease · 2023Review
- Article
- Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia.Biomarker research · 2022Review
- Interaction between N6-methyladenosine and autophagy in the regulation of bone and tissue degeneration.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purposeN6-methyladenosine (m
methodsThe biological effects of BP on AML cells were detected by MTT and ApoLive-Glo™ multiplex assays. The role of BP in tumor growth was determined by a subcutaneous xenograft model. The ALKBH5/MLST8/EIF4EBP1 axis was identified as a potential BP target in AML via methylated RNA immunoprecipitation sequencing (MeRIP-seq) combined with RNA sequencing (RNA-seq). Western blot, RT-qPCR, MeRIP-qPCR, dual-luciferase reporter and RNA stability assays were performed to validate the function and mode of action of the BP-regulated ALKBH5/MLST8/EIF4EBP1 axis. The clinical relevance of the BP-regulated ALKBH5/MLST8/EIF4EBP1 axis in AML was confirmed by TCGA data analysis.
resultsWe found that BP can inhibit AML cell proliferation and promote apoptosis in vitro, and repress AML tumor growth in vivo. Mechanistically, we found that BP downregulated ALKBH5 expression, which in turn repressed m
conclusionsOur data indicate that BP can inhibit acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.